BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Harvard Business School
Chinese Patent Office
UBS
Cantor Fitzgerald
Accenture
Argus Health
Boehringer Ingelheim
US Department of Justice

Generated: January 19, 2018

DrugPatentWatch Database Preview

Merck And Co Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MERCK AND CO INC, and when can generic versions of MERCK AND CO INC drugs launch?

MERCK AND CO INC has two approved drugs.

There is one US patent protecting MERCK AND CO INC drugs on MERCK AND CO INC drugs in the past three years.

There are thirty-six patent family members on MERCK AND CO INC drugs in twenty-seven countries and two supplementary protection certificates in two countries.

Summary for Merck And Co Inc
International Patents:36
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 13

Drugs and US Patents for Merck And Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-004 Oct 20, 2000 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-001 Sep 29, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-005 Oct 20, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-002 Sep 29, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Merck And Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-002 Sep 29, 1995 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-001 Sep 29, 1995 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-001 Sep 29, 1995 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-005 Oct 20, 2000 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-003 Apr 25, 1997 ➤ Subscribe ➤ Subscribe
Merck And Co Inc FOSAMAX alendronate sodium TABLET;ORAL 020560-005 Oct 20, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MERCK AND CO INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Oral Suspension 125 mg/Kit ➤ Subscribe 11/23/2016
➤ Subscribe Injection 115 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Injection 150 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Capsule 40 mg, 80 mg and 125 mg ➤ Subscribe 11/3/2008
➤ Subscribe Oral Solution 70 mg/75 mL ➤ Subscribe 9/7/2007

Non-Orange Book US Patents for Merck And Co Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Subscribe
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists ➤ Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Merck And Co Inc Drugs

Supplementary Protection Certificates for Merck And Co Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/021 United Kingdom ➤ Subscribe PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0019 France ➤ Subscribe PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
McKinsey
US Army
Moodys
US Department of Justice
Queensland Health
Accenture
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot